PMID- 24838151
OWN - NLM
STAT- MEDLINE
DCOM- 20150909
LR  - 20211021
IS  - 1532-2807 (Electronic)
IS  - 1219-4956 (Linking)
VI  - 21
IP  - 1
DP  - 2015 Jan
TI  - Autophagy interplays with apoptosis and cell cycle regulation in the growth 
      inhibiting effect of Trisenox in HEP-2, a laryngeal squamous cancer.
PG  - 103-11
LID - 10.1007/s12253-014-9794-6 [doi]
AB  - Laryngeal squamous cell carcinoma (LSCC) is the most common among several types 
      of head and neck cancers. Current treatments have a poor effect on early and 
      advanced cases, and further investigations for novel agents against LSCCs are 
      desirable. In this study, we elucidate the cytotoxic enhancing effect of arsenic 
      trioxide (As2O3) combined with L-buthionine sulfoximine (BSO) in LSCC. The effect 
      of BSO with As2O3 or Cisplatin (CDDP) on cell viability was examined using 
      3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). The reactive 
      oxygen species (ROS) levels, cell cycle, and apoptosis were measured by flow 
      cytometry using 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA), propidium 
      iodide (PI) and annexin V/PI. The acidic vacuolar organelles were visualized by 
      fluorescence microscope and quantified using flow cytometry. Neither CDDP nor 
      As2O3 when used alone reduced the cell viability. BSO was found to enhance only 
      As2O3 sensitivity, leading to G2/M arrest and autophagy with no correlation of 
      ROS induction. This result suggests that modulation of glutathione enhances 
      autophagy, which interplays with apoptosis. In this study, we obtained initial 
      preclinical evidence for the potential efficacy of these drugs in a combined 
      therapy protocol.
FAU - Pereira, Debora Lima
AU  - Pereira DL
AD  - Departamento de Estomatologia, Hospital AC Camargo, Sao Paulo, Brazil.
FAU - Dos Santos Ferreira, Ana Carolina
AU  - Dos Santos Ferreira AC
FAU - de Faria, Giselle Pinto
AU  - de Faria GP
FAU - Kwee, Jolie Kiemlian
AU  - Kwee JK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140518
PL  - Switzerland
TA  - Pathol Oncol Res
JT  - Pathology oncology research : POR
JID - 9706087
RN  - 0 (Arsenicals)
RN  - 0 (Oxides)
RN  - 0 (Reactive Oxygen Species)
RN  - Q20Q21Q62J (Cisplatin)
RN  - S7V92P67HO (Arsenic Trioxide)
SB  - IM
MH  - Apoptosis/*drug effects
MH  - Arsenic Trioxide
MH  - Arsenicals/*pharmacology
MH  - Autophagy/*drug effects
MH  - Carcinoma, Squamous Cell/*drug therapy/metabolism
MH  - Cell Cycle/*drug effects
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects
MH  - Cisplatin/pharmacology
MH  - Head and Neck Neoplasms/*drug therapy/metabolism
MH  - Humans
MH  - Laryngeal Neoplasms/*drug therapy/metabolism
MH  - Oxides/*pharmacology
MH  - Reactive Oxygen Species/metabolism
MH  - Squamous Cell Carcinoma of Head and Neck
EDAT- 2014/05/20 06:00
MHDA- 2015/09/10 06:00
CRDT- 2014/05/20 06:00
PHST- 2013/09/23 00:00 [received]
PHST- 2014/05/06 00:00 [accepted]
PHST- 2014/05/20 06:00 [entrez]
PHST- 2014/05/20 06:00 [pubmed]
PHST- 2015/09/10 06:00 [medline]
AID - 10.1007/s12253-014-9794-6 [doi]
PST - ppublish
SO  - Pathol Oncol Res. 2015 Jan;21(1):103-11. doi: 10.1007/s12253-014-9794-6. Epub 
      2014 May 18.